MedTrace Logo

Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer

NCT05616533 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-12-26

No results posted yet for this study

Summary

The goal of this study is to compare the tumor response in gastric cancer patients given neoadjuvant chemotherapy with the corresponding result obtained from zebrafish patient-derived tumor xenograft(PDX) model given the same regimen. The main question it aims to answer is whether this PDX model of zebrafish could accurately predict the effect of chemotherapy in advanced gastric cancer. Participants will be given the standard neoadjuvant treatment administrated by their own doctors and tumor response will be observed and recorded. Meanwhile, tumor samples derived from patients before chemotherapy will be transplanted to zebrafish and the same regimen will be given to the PDX models correspondingly. The tumor response data both from clinical practice and PDX model platform will be analysed and compared to evaluate the power of this zebrafish model platform in drug efficiency prediction.

Conditions

  • Precise Prediction of Therapy Efficiency

Interventions

OTHER

biopsy of tumor before treatment

samples obtained from biopsy will be used in the zebrafish PDX model

Sponsors & Collaborators

  • Hangzhou Hunter Biotechnology Incorporation

    collaborator UNKNOWN

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Xiaoli Jin, Dr · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2024-09-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616533 on ClinicalTrials.gov